Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National ...

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Protein complex in bacterial cell membrane acts like a rotary motor to recruit DNA-degrading enzymes to defend against phage ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have made a breakthrough in ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...